Drug Combo Shows Benefits in Rare, Aggressive Kidney Cancer

By News Health
4 weeks Ago

(MedPage Today) — The combination of investigational sintilimab with axitinib (Inlyta) showed promise in patients with fumarate hydratase (FH)-deficient renal cell carcinoma (RCC), according to a phase II nonrandomized trial in China.
Among 41…

Source link : https://www.medpagetoday.com/hematologyoncology/renalcellcarcinoma/117022

Author :

Publish date : 2025-08-15 18:21:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

What Hospitalists Need to Know, Do to Improve Stroke Care

Short Antibiotic Courses Match Long Ones in Solid Tumors

Geoengineering is not going to save the poles from climate change

Immunotherapy Safe for Children With Venom Allergy

Obesity Triples Odds of High Blood Pressure in Children

Serena Williams Sparks Debate Over GLP-1 Promotion